2025 India Acute Migraine Drugs Market Revenue Opportunities Report
Description
The 2025 India Acute Migraine Drugs Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Acute Migraine Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the acute migraine drugs market in India include Pfizer, Teva Pharmaceutical Industries, Johnson & Johnson, and GlaxoSmithKline (GSK). Pfizer is notable for its recent FDA approval of Zavzpret, the first CGRP receptor antagonist nasal spray for acute migraine treatment, reflecting innovation relevant to the Indian market's growing demand. Teva is advancing with AJOVY (fremanezumab), a CGRP antagonist targeting both adult and pediatric migraine prevention, with strong clinical trial support and regional market expansion efforts in Asia. Johnson & Johnson and GSK continue to hold significant market shares and contribute to migraine drug development and distribution, leveraging India’s fast-growing migraine market.
These companies capitalize on India's expanding migraine drugs market, projected to reach over USD 400 million by 2030 with a CAGR exceeding 12%, fueled by increased migraine prevalence and expanding awareness. Their strategic focus includes launching innovative therapies such as CGRP antagonists, triptans, and combination drugs offering rapid symptom relief. The Indian market also exhibits strong growth in OTC migraine products, providing these firms avenues for both prescription and non-prescription sales. Additionally, digital health solutions and telemedicine are emerging trends helping these firms enhance patient access and adherence in India’s price-sensitive and diverse healthcare landscape.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Acute Migraine Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the acute migraine drugs market in India include Pfizer, Teva Pharmaceutical Industries, Johnson & Johnson, and GlaxoSmithKline (GSK). Pfizer is notable for its recent FDA approval of Zavzpret, the first CGRP receptor antagonist nasal spray for acute migraine treatment, reflecting innovation relevant to the Indian market's growing demand. Teva is advancing with AJOVY (fremanezumab), a CGRP antagonist targeting both adult and pediatric migraine prevention, with strong clinical trial support and regional market expansion efforts in Asia. Johnson & Johnson and GSK continue to hold significant market shares and contribute to migraine drug development and distribution, leveraging India’s fast-growing migraine market.
These companies capitalize on India's expanding migraine drugs market, projected to reach over USD 400 million by 2030 with a CAGR exceeding 12%, fueled by increased migraine prevalence and expanding awareness. Their strategic focus includes launching innovative therapies such as CGRP antagonists, triptans, and combination drugs offering rapid symptom relief. The Indian market also exhibits strong growth in OTC migraine products, providing these firms avenues for both prescription and non-prescription sales. Additionally, digital health solutions and telemedicine are emerging trends helping these firms enhance patient access and adherence in India’s price-sensitive and diverse healthcare landscape.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
